Newsroom

AUGUST 29, 2018 Glytec Receives Two More Patent Allowances for its Insulin Optimization System The newest USPTO allowances describe an integrated, connected care model for optimizing insulin therapy in the outpatient setting. Waltham, MA — The United States Patent and Trademark Office has awarded Glytec two more patent allowances acknowledging the unique characteristics of its disruptive...

JANUARY 9, 2018 USPTO Grants Glytec Patent Allowance for Computer-Guided Selection and Dosing of All Diabetes Medications The new patent allowance addresses personalized optimization of insulin and non-insulin medications alike. Waltham, MA — Long recognized as the market leader in enterprise software solutions for insulin management, Glytec is expanding its intellectual property protections...

JANUARY 5, 2018 Glytec Awarded Patent Allowance Supporting Connected Care Model for Insulin Management The allowed patent encompasses detailed interactions between multiple connected diabetes technologies. Waltham, MA — Glytec, the pioneer of personalized digital therapeutics, has been awarded another U.S. patent allowance for systems and methods related to insulin management in the outpatient...

AUGUST 16, 2017 Glytec Announces Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software The company’s eGlycemic Management System® featuring Glucommander™ has the broadest indications for use of any decision support solution for insulin titration. WALTHAM, MA — The pioneer of diabetes therapy management software, Glytec announces its fourth FDA clearance, adding...

The allowed claims are directed to a system for glycemic control of a diabetic patient that includes a smartphone-based diabetes mobile application, which will provide patients with real-time insulin dosing guidance, leveraging Glytec’s proprietary insulin titration technology. Waltham, MA — Glytec, the pioneer and leader in providing innovative glucose management software solutions,...